Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Recruiting 2Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 156Neoplasms 115Colorectal Neoplasms 98Breast Neoplasms 93Pancreatic Neoplasms 81Neoplasm Metastasis 81Leukemia, Myeloid, Acute 79Recurrence 76Prostatic Neoplasms 74Ovarian Neoplasms 74Melanoma 74Multiple Myeloma 66Stomach Neoplasms 59Lung Neoplasms 56Squamous Cell Carcinoma of Head and Neck 55Triple Negative Breast Neoplasms 50Glioblastoma 49Lymphoma 47Endometrial Neoplasms 43Carcinoma, Hepatocellular 42Advanced Solid Tumor 42Lymphoma, Non-Hodgkin 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Advanced Solid Tumors 37Small Cell Lung Carcinoma 35Uterine Cervical Neoplasms 34Carcinoma, Renal Cell 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, B-Cell 32Sarcoma 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Blastic Plasmacytoid Dendritic Cell Neoplasm × Clear all
NCT07523555 2026-04-13

ADAPT-HEM

Beijing Biotech

Phase 1/2 Recruiting
96 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Plasma Cell, Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06006403 2023-08-30

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Chongqing Precision Biotech Co., Ltd

Phase 1/2 Recruiting
36 enrolled
MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡